ROIV Roivant Sciences Ltd.
USHealthcareAs of 2026-10-08
Why ROIV matters now
Roivant Sciences Ltd. (ROIV) is a US stock in Healthcare. The latest InvestLog snapshot shows $34.21 with -1.55% on the session and $24.71B in market capitalization; recent performance reads 1-month +11.41% and YTD +44.84%.
The latest financial table shown here is Q4 2025, with revenue of $2.5M, net income of $303.0M, and EPS of $0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.4%.
InvestLog's latest related AI research is a Rating Change note titled "Stifel initiates coverage of ROIV with Buy". The latest indexable market news headline is "Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.00; recent insider activity includes Venker Eric filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.87
P/S
2736.88
EV/EBITDA
-81.50
DCF Value
$2.90
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.4%
Operating Margin
-15560.6%
Net Margin
-3629.2%
ROE
-6.9%
ROA
-5.2%
ROIC
-23.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.5M | $303.0M | $0.37 |
| FY 2025 | $8.3M | $-299.8M | $-0.43 |
| Q3 2025 | $2.0M | $-265.9M | $-0.38 |
| Q2 2025 | $1.6M | $-113.5M | $-0.17 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$37.17
Target (Median)
$38.00
Target Range
$30.00 - $42.00
Trading Activity
Insider Trades
Related AI Research
Stifel initiates coverage of ROIV with BuyStifel 首次覆盖 ROIV，初始评级 买入（Buy）
On 2026-09-16, Stifel initiated coverage of ROIV with a Buy rating.Stifel 于 2026-09-16 首次覆盖 ROIV，初始评级为 买入（Buy）。
TD Cowen raises ROIV target to $55TD Cowen 上调目标价 ROIV 至 $55
On 2026-09-09, TD Cowen raised its ROIV price target to $55.TD Cowen 于 2026-09-09 将 ROIV 目标价上调至 $55。
Guggenheim raises ROIV target to $46Guggenheim 上调目标价 ROIV 至 $46
On 2026-09-09, Guggenheim raised its ROIV price target to $46.Guggenheim 于 2026-09-09 将 ROIV 目标价上调至 $46。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
—
Beta
1.14
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.